Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours
about
Depot-Based Delivery Systems for Pro-Angiogenic Peptides: A ReviewBeta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes.Tension in CancerIntegrins in the Spotlight of CancerIntegrins in cancer: biological implications and therapeutic opportunitiesSignificance of talin in cancer progression and metastasis.RGD-Binding Integrins in Head and Neck Cancers.α5β1 integrin signaling mediates oxidized low-density lipoprotein-induced inflammation and early atherosclerosis.Integrin alpha(v)beta(3)-Targeted Cancer Therapy.Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancerIncreased potency of the PHSCN dendrimer as an inhibitor of human prostate cancer cell invasion, extravasation, and lung colony formationAnti-angiogenic peptides for cancer therapeuticsTargeting tumor cell motility to prevent metastasis.Role of α(5)β(1) Integrin Up-regulation in Radiation-Induced Invasion by Human Pancreatic Cancer CellsRecombinant disintegrin (r-Cam-dis) from Crotalus adamanteus inhibits adhesion of human pancreatic cancer cell lines to laminin-1 and vitronectin.Integrin inhibitors as a therapeutic agent for ovarian cancerβ1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer.Angiogenesis blockade as a new therapeutic approach to experimental colitis.The mesenchymal tumor microenvironment: a drug-resistant niche.Angiogenesis in melanoma.Integrins and metastasis.alpha(5)beta(1) Integrin Ligand PHSRN Induces Invasion and alpha(5) mRNA in Endothelial Cells to Stimulate AngiogenesisIntegrins in angiogenesis and lymphangiogenesisMolecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth.Novel strategies for the treatment of chondrosarcomas: targeting integrins.Targeting integrin α5β1 ameliorates severe airway hyperresponsiveness in experimental asthma.Integrins as receptor targets for neurological disordersRGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors.Identification of curcumin-inhibited extracellular matrix receptors in non-small cell lung cancer A549 cells by RNA sequencing.New therapeutic targets for cancer bone metastasisIntegrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation.Inside the Cell: Integrins as New Governors of Nuclear Alterations?Molecular Targeting of Integrins and Integrin-Associated Signaling Networks in Radiation Oncology.The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer.Modes of invasion during tumour dissemination.Hypoxia Selectively Enhances Integrin α5β1 Receptor Expression in Breast Cancer to Promote MetastasisIntegrin α5 triggers the metastatic potential in renal cell carcinoma.Therapeutic inhibition of breast cancer bone metastasis progression and lung colonization: breaking the vicious cycle by targeting α5β1 integrin.β1 and β3 integrins in breast, prostate and pancreatic cancer: A novel implication.
P2860
Q26799856-63A9EAA3-9119-40AC-8851-2DC32BC5A9FBQ27342529-0A3375DF-B6DE-41D4-9AF5-B12DA5EE0AF7Q28066437-05B2C8CB-4C80-46F2-83F8-12CFDD54EF07Q28066805-609DF8BB-4303-4E74-B709-ED892161FFBDQ29614536-635A3B20-285A-4E5F-987D-6DB27167107AQ33763551-5EE49EF4-73AD-4504-8F56-BC808495847BQ33832735-22D7BA6E-7029-432E-B1A5-1434C67959A8Q33896730-A8A11A90-6E2A-4FAB-9114-F1DC2ABBAFBFQ33983773-40806ABD-EF7D-433F-BBF3-D9F9A255D570Q34128953-C1D4D6E2-BD83-494F-A565-C90B49349463Q34649015-196887B4-CC20-4BBE-8F21-6C4ACE4EFDC4Q35043016-FA79EE9C-7E9B-410A-99C9-4C738088B42BQ35095152-A54FC519-C838-46A7-A49E-DAEAD829D12DQ35182588-C6675C71-558E-4C9C-AC79-45A3D71E8717Q35634200-6B9F3D9A-0B65-4A3D-B728-2B03DE9F298EQ35660004-B406C624-84F9-4B1B-A2BD-A823F60D6150Q35889538-5D8959A1-E342-47E6-A671-5D62F8DE15E9Q35953816-B1B51850-3569-419D-BCA8-2DA015C6B3B4Q36187755-D1C1D7B2-0B6C-4BCE-9EA1-AEF588FD7073Q36626892-9EE90E2F-F3D8-4109-8377-54368403E9FDQ37014793-8E390CEF-EB21-4B04-AC86-086FAF60B2CCQ37109451-93A15DDD-13A9-4E21-888D-0AF716455E8AQ37170752-F15FBB92-F663-4122-8BE1-DDC09EAE9FDAQ37328406-A2128002-C49E-467E-8879-01F1E8310F26Q37486731-D41C1668-31C4-4CB5-BF55-5A9421D813E7Q37544994-30C3B86E-082B-473C-BAF6-E6D2037C61B7Q37974737-5F645C8D-4579-4597-B84F-C8BDB6BEC673Q38161395-DCE6C1C8-809B-47C8-BCE9-08B23488B316Q38161726-6F6DD2B9-6DBA-4E99-8770-7910231846AAQ38432455-7F73D3AE-F5D6-49E6-9C53-EDA0DF046A42Q38473066-727C696B-6C2C-4C66-8D03-6A2EDC43DADBQ38501776-3C455C4B-EDD5-460E-A110-8AD1CE7955E3Q38690278-F20BD7D7-6704-4859-AD88-A1688E4062BCQ38869424-AE7B498C-2975-405E-8A78-52AD4F1697ABQ38981265-64E17F40-AA4C-4559-B971-D1062F890AB6Q39085737-AD280884-7D23-47AD-84E7-9F294A4A5C3EQ41015404-EF4E39B9-FE6B-4DCC-A065-F25B45C83FFFQ47140682-BCBEC57B-3C3B-49DD-8F16-A8733BD7C66CQ51723599-F37FBB41-96B6-408A-B16C-178DF249F029Q52647715-637B8077-26E8-428E-A50F-D7ED70A421F4
P2860
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Phase 1 trial of the antiangio ...... in patients with solid tumours
@ast
Phase 1 trial of the antiangio ...... in patients with solid tumours
@en
type
label
Phase 1 trial of the antiangio ...... in patients with solid tumours
@ast
Phase 1 trial of the antiangio ...... in patients with solid tumours
@en
prefLabel
Phase 1 trial of the antiangio ...... in patients with solid tumours
@ast
Phase 1 trial of the antiangio ...... in patients with solid tumours
@en
P2093
P2860
P356
P1476
Phase 1 trial of the antiangio ...... in patients with solid tumours
@en
P2093
K A Kimmel
M E Cianfrocca
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603171
P407
P577
2006-06-01T00:00:00Z
P5875
P6179
1009761935